1. Pink Sheet

Why Big Pharma Will Continue To Choose India For Clinical Research In 2025

Rare Disease Opportunity

 
• By Vibha Ravi

Faster approvals and regulatory flexibility are among moves India has made to draw clinical trial investments. As MNCs seek to replace products close to patent expiry with new blockbusters and domestic companies tap unmet needs, how will the R&D landscape shape up in 2025?

India Is Gaining Importance As A Clinical Trials Destination
R&D Activity In India Is Expected To Gain Pace (Shutterstock)

India’s role both as a clinical trials destination and a marketplace is seen amplifying as multinational companies (MNCs) rely on a combination of in-house R&D and acquisitions to restock a depleting arsenal of blockbusters.

Meanwhile, Indian majors are seeking to develop novel molecules keeping in mind not just the country’s disease profile, but also the global commercial potential of candidates, ranging from antibiotics to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pink Sheet Perspectives

More from Geography

UroGen’s Bladder Cancer Drug Draws Split Decision From US FDA Panel

 
• By Sue Sutter

The Oncologic Drugs Advisory Committee voted 5-4 that the overall benefit-risk of UGN-102 is not favorable in patients with recurrent low grade, intermediate-risk, non-muscle invasive bladder cancer and also divided on whether randomized trials should be required for future development programs.

US FDA Will Help States Apply To Import Cheaper Drugs From Canada

 
• By Cathy Kelly

The FDA is not currently signaling that stringent rules for the process will be relaxed, but the agency's change in approach is notable.

Global Pandemic Deal Adopted As 124 Countries Say Yes; US Sits Out

 
• By Neena Brizmohun

Now that the landmark Pandemic Agreement has finally been adopted, work will start on drafting a pathogen access and benefit sharing system that will be voluntary for use by drug companies.